相似文献
1
Recurrent Glomerular Disease after Kidney Transplantation: Diagnostic and Management Dilemmas.
Clin J Am Soc Nephrol. 2021 Nov;16(11):1730-1742. doi: 10.2215/CJN.00280121. Epub 2021 Oct 22.
2
Recurrent glomerular disease after kidney transplantation.
Curr Opin Nephrol Hypertens. 2017 Nov;26(6):501-508. doi: 10.1097/MNH.0000000000000358.
3
Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation.
Nephrology (Carlton). 2015 Jul;20 Suppl 2:61-5. doi: 10.1111/nep.12465.
4
A case of atypical hemolytic uremic syndrome in a second renal transplant.
J Nephrol. 2018 Feb;31(1):165-172. doi: 10.1007/s40620-016-0373-7. Epub 2017 Feb 21.
5
Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16.
6
Liver transplantation for aHUS: still needed in the eculizumab era?
Pediatr Nephrol. 2016 May;31(5):759-68. doi: 10.1007/s00467-015-3278-0. Epub 2015 Nov 24.
7
Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
Clin Nephrol. 2020 Jan;93(1):51-56. doi: 10.5414/CN109890.
8
The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation.
J Ayub Med Coll Abbottabad. 2021 Apr-Jun;33(2):315-318.
9
Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Transplant Proc. 2017 Jan-Feb;49(1):159-162. doi: 10.1016/j.transproceed.2016.10.013.
10
Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776.
引用本文的文献
1
Construction of LncRNA-miRNA-mRNA regulatory network in IgA nephropathy mice model by RNA-sequencing and bioinformatics analysis.
Genes Genomics. 2025 Aug 18. doi: 10.1007/s13258-025-01670-7.
2
C3 glomerulopathy post kidney transplantation: A single center experience.
World J Transplant. 2025 Jun 18;15(2):101517. doi: 10.5500/wjt.v15.i2.101517.
3
Kidney transplant in patients with C3 glomerulopathy.
Clin Kidney J. 2025 Apr 30;18(5):sfaf134. doi: 10.1093/ckj/sfaf134. eCollection 2025 May.
4
Complement-Mediated Kidney Disease and Living Donor Transplantation: Tailoring Approaches to Improve Outcomes.
Curr Transplant Rep. 2025;12(1). doi: 10.1007/s40472-025-00466-8. Epub 2025 Apr 16.
5
Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.
Clin Kidney J. 2024 Oct 24;17(12):sfae320. doi: 10.1093/ckj/sfae320. eCollection 2024 Dec.
6
Access to Waitlisting and Posttransplant Outcomes in Patients With Failed Kidney Allografts Secondary to Recurrent Glomerulonephritis.
Transplant Direct. 2024 Oct 18;10(11):e1717. doi: 10.1097/TXD.0000000000001717. eCollection 2024 Nov.
7
CRISPR-enabled point-of-care genotyping for APOL1 genetic risk assessment.
EMBO Mol Med. 2024 Oct;16(10):2619-2637. doi: 10.1038/s44321-024-00126-x. Epub 2024 Sep 13.
8
Identification of Pathogenic Pathways for Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation.
Diagnostics (Basel). 2024 Jul 24;14(15):1591. doi: 10.3390/diagnostics14151591.
9
A pragmatic approach to selective genetic testing in kidney transplant candidates.
Front Transplant. 2024 Jan 16;2:1342471. doi: 10.3389/frtra.2023.1342471. eCollection 2023.
10
Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.
Int J Mol Sci. 2024 Jun 13;25(12):6508. doi: 10.3390/ijms25126508.
Zotero 插件